{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:23:46Z","timestamp":1790659426042,"version":"4.1.0"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2022LSW023"],"award-info":[{"award-number":["ZR2022LSW023"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bmc.2025.118372","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:53:36Z","timestamp":1756277616000},"page":"118372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Advances of HDAC dual inhibitors in breast cancer treatment"],"prefix":"10.1016","volume":"130","author":[{"given":"Chuanjiang","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoni","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bmc.2025.118372_bb0005","first-page":"524","article-title":"Breast Cancer statistics, 2022","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bmc.2025.118372_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106535","article-title":"Breast cancer: biology, biomarkers, and treatments","volume":"84","author":"Barzaman","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"10.1016\/j.bmc.2025.118372_bb0015","first-page":"438","article-title":"Breast cancer statistics, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"10286","key":"10.1016\/j.bmc.2025.118372_bb0020","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2025.118372_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101312","article-title":"HDAC inhibitors: targets for tumor therapy, immune modulation and lung diseases","volume":"16","author":"Shanmugam","year":"2022","journal-title":"Transl Oncol"},{"key":"10.1016\/j.bmc.2025.118372_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115418","article-title":"HDAC11: a novel target for improved cancer therapy","volume":"166","author":"Liu","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"10.1016\/j.bmc.2025.118372_bb0035","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1007\/s43032-021-00773-2","article-title":"Modulation of placental breast cancer resistance protein by HDAC1 in mice: implications for optimization of pharmacotherapy during pregnancy","volume":"28","author":"Wang","year":"2021","journal-title":"Reprod Sci"},{"issue":"17","key":"10.1016\/j.bmc.2025.118372_bb0040","doi-asserted-by":"crossref","first-page":"12033","DOI":"10.1021\/acs.jmedchem.3c00614","article-title":"Selective HDAC3 inhibitors with potent in vivo antitumor efficacy against triple-negative breast cancer","volume":"66","author":"Pulya","year":"2023","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.bmc.2025.118372_bb0045","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s43018-022-00489-5","article-title":"Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer","volume":"4","author":"Zeleke","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.bmc.2025.118372_bb0050","doi-asserted-by":"crossref","unstructured":"Li, Y.; Seto, E., HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med 2016, 6 (10) 0.","DOI":"10.1101\/cshperspect.a026831"},{"key":"10.1016\/j.bmc.2025.118372_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104462","article-title":"Investigation of the effect of different linker chemotypes on the inhibition of histone deacetylases (HDACs)","volume":"106","author":"Linciano","year":"2021","journal-title":"Bioorg Chem"},{"issue":"37","key":"10.1016\/j.bmc.2025.118372_bb0060","doi-asserted-by":"crossref","first-page":"26926","DOI":"10.1074\/jbc.M113.490706","article-title":"Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability","volume":"288","author":"Lauffer","year":"2013","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.bmc.2025.118372_bb0065","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.14366","article-title":"Discussion on structure classification and regulation function of histone deacetylase and their inhibitor","volume":"103","author":"Han","year":"2024","journal-title":"Chem Biol Drug Des"},{"issue":"11","key":"10.1016\/j.bmc.2025.118372_bb0070","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1042\/CS20120504","article-title":"Histone deacetylases as targets for treatment of multiple diseases","volume":"124","author":"Tang","year":"2013","journal-title":"Clin Sci (Lond)"},{"issue":"6","key":"10.1016\/j.bmc.2025.118372_bb0075","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.leukres.2009.08.021","article-title":"Histone deacetylase inhibitors: a new perspective for the treatment of leukemia","volume":"34","author":"Abujamra","year":"2010","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.bmc.2025.118372_bb0080","first-page":"1027","article-title":"A novel HDAC1 inhibitor, CBUD-1001, exerts anticancer effects by modulating the apoptosis and EMT of colorectal cancer cells","volume":"57","author":"Kim","year":"2020","journal-title":"Int J Oncol"},{"issue":"6","key":"10.1016\/j.bmc.2025.118372_bb0085","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","article-title":"Targeting histone deacetylases for cancer therapy: trends and challenges","volume":"13","author":"Liang","year":"2023","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"10.1016\/j.bmc.2025.118372_bb0090","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00280-021-04298-y","article-title":"A triple combination gemcitabine+romidepsin+cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis","volume":"88","author":"Pattarawat","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bmc.2025.118372_bb0095","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.breast.2022.10.018","article-title":"Clinical outcomes of tucidinostat-based therapy after prior CDK4\/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer","volume":"66","author":"Zhou","year":"2022","journal-title":"Breast"},{"issue":"28","key":"10.1016\/j.bmc.2025.118372_bb0100","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1200\/JCO.21.00944","article-title":"E2112: randomized phase III trial of endocrine therapy plus entinostat or placebo in hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN Cancer research group","volume":"39","author":"Connolly","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2025.118372_bb0105","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejmech.2017.05.016","article-title":"Designing multi-targeted agents: an emerging anticancer drug discovery paradigm","volume":"136","author":"Fu","year":"2017","journal-title":"Eur J Med Chem"},{"issue":"2","key":"10.1016\/j.bmc.2025.118372_bb0110","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40264-018-0773-9","article-title":"Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology","volume":"42","author":"Shah","year":"2019","journal-title":"Drug Saf"},{"issue":"11","key":"10.1016\/j.bmc.2025.118372_bb0115","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.tig.2021.05.002","article-title":"Navigating the DNA methylation landscape of cancer","volume":"37","author":"Nishiyama","year":"2021","journal-title":"Trends Genet"},{"issue":"1","key":"10.1016\/j.bmc.2025.118372_bb0120","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/s41467-021-22024-3","article-title":"Epigenetic mechanisms in breast cancer therapy and resistance","volume":"12","author":"Garcia-Martinez","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.bmc.2025.118372_bb0125","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1021\/acs.jmedchem.2c01191","article-title":"BET-HDAC dual inhibitors for combinational treatment of breast cancer and concurrent candidiasis","volume":"66","author":"Huang","year":"2023","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.bmc.2025.118372_bb0130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrg.2017.80","article-title":"The DNA methyltransferase family: a versatile toolkit for epigenetic regulation","volume":"19","author":"Lyko","year":"2018","journal-title":"Nat Rev Genet"},{"issue":"1","key":"10.1016\/j.bmc.2025.118372_bb0135","doi-asserted-by":"crossref","first-page":"6731","DOI":"10.1038\/s41467-023-42417-w","article-title":"DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts","volume":"14","author":"Goyal","year":"2023","journal-title":"Nat Commun"},{"issue":"20","key":"10.1016\/j.bmc.2025.118372_bb0140","doi-asserted-by":"crossref","first-page":"5176","DOI":"10.1158\/0008-5472.CAN-20-4243","article-title":"Epigenetic therapies in ovarian cancer alter repetitive element expression in a TP53-dependent manner","volume":"81","author":"McDonald","year":"2021","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.bmc.2025.118372_bb0145","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.62347\/IDKG8587","article-title":"The inhibitory and transcriptional effects of the epigenetic repurposed drugs hydralazine and valproate in lymphoma cells","volume":"14","author":"Salamanca-Ortiz","year":"2024","journal-title":"Am J Cancer Res"},{"issue":"1","key":"10.1016\/j.bmc.2025.118372_bb0150","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11912-024-01623-5","article-title":"Epigenetic role of long non-coding RNAs in multiple myeloma","volume":"27","author":"Mehra","year":"2025","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"10.1016\/j.bmc.2025.118372_bb0155","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s12032-022-01765-1","article-title":"Epigenetic restoration and activation of ER\u03b2: an inspiring approach for treatment of triple-negative breast cancer","volume":"39","author":"Salahuddin","year":"2022","journal-title":"Med Oncol"},{"issue":"1","key":"10.1016\/j.bmc.2025.118372_bb0160","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41420-024-01895-7","article-title":"Dual inhibitors of DNMT and HDAC induce viral mimicry to induce antitumour immunity in breast cancer","volume":"10","author":"Huang","year":"2024","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.bmc.2025.118372_bb0165","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bioorg.2019.03.027","article-title":"Development of a versatile DNMT and HDAC inhibitor C02S modulating multiple cancer hallmarks for breast cancer therapy","volume":"87","author":"Yuan","year":"2019","journal-title":"Bioorg Chem"},{"issue":"1","key":"10.1016\/j.bmc.2025.118372_bb0170","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13072-022-00446-7","article-title":"Structural and functional specificity of H3K36 methylation","volume":"15","author":"Lam","year":"2022","journal-title":"Epigenetics Chromatin"},{"issue":"6","key":"10.1016\/j.bmc.2025.118372_bb0175","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.molcel.2005.08.027","article-title":"Regulation of LSD1 histone demethylase activity by its associated factors","volume":"19","author":"Shi","year":"2005","journal-title":"Mol Cell"},{"key":"10.1016\/j.bmc.2025.118372_bb0180","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ejmech.2017.09.038","article-title":"Design and synthesis of tranylcypromine derivatives as novel LSD1\/HDACs dual inhibitors for cancer treatment","volume":"140","author":"Duan","year":"2017","journal-title":"Eur J Med Chem"},{"issue":"7","key":"10.1016\/j.bmc.2025.118372_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071753","article-title":"Reduction of metastasis via epigenetic modulation in a murine model of metastatic triple negative breast cancer (TNBC)","volume":"14","author":"Zylla","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.bmc.2025.118372_bb0190","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.trechm.2019.07.002","article-title":"The structure and function of DNA G-quadruplexes","volume":"2","author":"Spiegel","year":"2020","journal-title":"Trends Chem"},{"issue":"5","key":"10.1016\/j.bmc.2025.118372_bb0195","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.bmc.2025.118372_bb0200","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cmet.2017.09.009","article-title":"MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation","volume":"26","author":"Lee","year":"2017","journal-title":"Cell Metab"},{"issue":"18","key":"10.1016\/j.bmc.2025.118372_bb0205","doi-asserted-by":"crossref","first-page":"12346","DOI":"10.1021\/acs.jmedchem.2c01058","article-title":"Discovery of a novel G-quadruplex and histone deacetylase (HDAC) dual-targeting agent for the treatment of triple-negative breast cancer","volume":"65","author":"Jiang","year":"2022","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.bmc.2025.118372_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27072294","article-title":"Quinazoline based HDAC dual inhibitors as potential anti-cancer agents","volume":"27","author":"Dhuguru","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2025.118372_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115915","article-title":"Discovery of benzamide-based PI3K\/HDAC dual inhibitors with marked pro-apoptosis activity in lymphoma cells","volume":"262","author":"Deng","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118372_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103334","article-title":"PI3K inhibition in breast cancer: identifying and overcoming different flavors of resistance","volume":"162","author":"Vitale","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.bmc.2025.118372_bb0225","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/jcmm.13935","article-title":"CUDC-907 blocks multiple pro-survival signals and abrogates microenvironment protection in CLL","volume":"23","author":"Chen","year":"2019","journal-title":"J Cell Mol Med"},{"issue":"4","key":"10.1016\/j.bmc.2025.118372_bb0230","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12079-020-00558-3","article-title":"CUDC-907 enhances TRAIL-induced apoptosis through upregulation of DR5 in breast cancer cells","volume":"14","author":"Li","year":"2020","journal-title":"J Cell Commun Signal"},{"issue":"5","key":"10.1016\/j.bmc.2025.118372_bb0235","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10541","article-title":"Quatramer\u2122 encapsulation of dual-targeted PI3-K\u03b4\/HDAC6 inhibitor, HSB-510, suppresses growth of breast cancer","volume":"8","author":"Tiwari","year":"2023","journal-title":"Bioeng Transl Med"},{"key":"10.1016\/j.bmc.2025.118372_bb0240","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejpb.2022.09.003","article-title":"Quatramer\u2122 mediated co-delivery of PI3-K\u03b4\/HDAC6 dual inhibitor augments the anti-cancer efficacy of Epirubicin in breast cancer","volume":"179","author":"Tiwari","year":"2022","journal-title":"Eur J Pharm Biopharm"},{"issue":"11","key":"10.1016\/j.bmc.2025.118372_bb0245","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.tips.2012.08.005","article-title":"JAK2 the future: therapeutic strategies for JAK-dependent malignancies","volume":"33","author":"LaFave","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bmc.2025.118372_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.bmc.2025.118372_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112677","article-title":"Design and synthesis of novel flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer","volume":"206","author":"Wei","year":"2020","journal-title":"Eur J Med Chem"},{"issue":"2","key":"10.1016\/j.bmc.2025.118372_bb0260","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1021\/acs.jmedchem.0c02111","article-title":"Discovery of novel pyrrolo[2,3-d]pyrimidine-based derivatives as potent JAK\/HDAC dual inhibitors for the treatment of refractory solid tumors","volume":"65","author":"Liang","year":"2021","journal-title":"J Med Chem"},{"issue":"8","key":"10.1016\/j.bmc.2025.118372_bb0265","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1021\/acs.jmedchem.8b01597","article-title":"Discovery of novel Janus kinase (JAK) and histone deacetylase (HDAC) dual inhibitors for the treatment of hematological malignancies","volume":"62","author":"Liang","year":"2019","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.bmc.2025.118372_bb0270","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.molcel.2015.10.013","article-title":"PARP-1 activation requires local unfolding of an autoinhibitory domain","volume":"60","author":"Dawicki-McKenna","year":"2015","journal-title":"Mol Cell"},{"key":"10.1016\/j.bmc.2025.118372_bb0275","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13058-015-0534-y","article-title":"Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells","volume":"17","author":"Min","year":"2015","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.bmc.2025.118372_bb0280","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41419-023-06303-z","article-title":"Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer","volume":"15","author":"Zhu","year":"2024","journal-title":"Cell Death Dis"},{"issue":"6","key":"10.1016\/j.bmc.2025.118372_bb0285","doi-asserted-by":"crossref","DOI":"10.3892\/or.2023.8563","article-title":"Nucleophosmin promotes lung adenocarcinoma cell proliferation, migration and invasion by activating the EGFR\/MAPK signaling pathway","volume":"49","author":"Li","year":"2023","journal-title":"Oncol Rep"},{"issue":"7","key":"10.1016\/j.bmc.2025.118372_bb0290","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00018-022-04417-9","article-title":"EWI2 prevents EGFR from clustering and endocytosis to reduce tumor cell movement and proliferation","volume":"79","author":"Fu","year":"2022","journal-title":"Cell Mol Life Sci"},{"issue":"8","key":"10.1016\/j.bmc.2025.118372_bb0295","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrc3309","article-title":"The ERBB network: at last, cancer therapy meets systems biology","volume":"12","author":"Yarden","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2025.118372_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.105166","article-title":"Synergistic efficacy of combined EGFR and HDAC inhibitors overcomes tolerance to EGFR monotherapy in salivary mucoepidermoid carcinoma","volume":"115","author":"Parag-Sharma","year":"2021","journal-title":"Oral Oncol"},{"issue":"1","key":"10.1016\/j.bmc.2025.118372_bb0305","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s12031-019-01280-5","article-title":"Combined inhibition of HDAC and EGFR reduces viability and proliferation and enhances STAT3 mRNA expression in glioblastoma cells","volume":"68","author":"Buendia Duque","year":"2019","journal-title":"J Mol Neurosci"},{"issue":"13","key":"10.1016\/j.bmc.2025.118372_bb0310","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24132407","article-title":"Synthesis and biological evaluation of novel osimertinib-based HDAC and EGFR dual inhibitors","volume":"24","author":"Dong","year":"2019","journal-title":"Molecules"},{"issue":"11","key":"10.1016\/j.bmc.2025.118372_bb0315","doi-asserted-by":"crossref","DOI":"10.3390\/ph14111177","article-title":"Design, synthesis, in vitro anticancer evaluation and molecular modelling studies of 3,4,5-trimethoxyphenyl-based derivatives as dual EGFR\/HDAC hybrid inhibitors","volume":"14","author":"Ibrahim","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"34","key":"10.1016\/j.bmc.2025.118372_bb0320","doi-asserted-by":"crossref","first-page":"13932","DOI":"10.1073\/pnas.1309629110","article-title":"Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth","volume":"110","author":"Yang","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.bmc.2025.118372_bb0325","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041232","article-title":"Resistance to anti-angiogenic therapy in cancer-alterations to anti-VEGF pathway","volume":"19","author":"Itatani","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"21","key":"10.1016\/j.bmc.2025.118372_bb0330","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-17-3766","article-title":"Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma","volume":"24","author":"Chi","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bmc.2025.118372_bb0335","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12943-022-01536-6","article-title":"Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-plus trial","volume":"21","author":"Wu","year":"2022","journal-title":"Mol Cancer"},{"issue":"41","key":"10.1016\/j.bmc.2025.118372_bb0340","doi-asserted-by":"crossref","first-page":"28462","DOI":"10.1039\/D3RA05542F","article-title":"Design, synthesis and biological evaluation of VEGFR-2\/HDAC dual inhibitors as multitargeted antitumor agents based on fruquintinib and vorinostat","volume":"13","author":"Gao","year":"2023","journal-title":"RSC Adv"},{"issue":"1","key":"10.1016\/j.bmc.2025.118372_bb0345","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13045-022-01310-7","article-title":"Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy","volume":"15","author":"Liu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bmc.2025.118372_bb0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2015.12.033","article-title":"Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC","volume":"109","author":"Peng","year":"2016","journal-title":"Eur J Med Chem"},{"issue":"22","key":"10.1016\/j.bmc.2025.118372_bb0355","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1016\/j.bmcl.2015.10.006","article-title":"Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase","volume":"25","author":"Peng","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"10.1016\/j.bmc.2025.118372_bb0360","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.bmc.2025.118372_bb0365","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1038\/s41467-022-30666-0","article-title":"Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer","volume":"13","author":"Coombes","year":"2022","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.bmc.2025.118372_bb0370","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.bmc.2017.12.041","article-title":"Design, synthesis and evaluate of novel dual FGFR1 and HDAC inhibitors bearing an indazole scaffold","volume":"26","author":"Liu","year":"2018","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"10.1016\/j.bmc.2025.118372_bb0375","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/biomedicines3010032","article-title":"c-Met and miRs in cancer","volume":"3","author":"Giglio","year":"2015","journal-title":"Biomedicines"},{"key":"10.1016\/j.bmc.2025.118372_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216780","article-title":"Unlocking c-MET: a comprehensive journey into targeted therapies for breast cancer","volume":"588","author":"Jabbarzadeh Kaboli","year":"2024","journal-title":"Cancer Lett"},{"issue":"8","key":"10.1016\/j.bmc.2025.118372_bb0385","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.20892\/j.issn.2095-3941.2021.0130","article-title":"The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKK\u03b1 and overcomes gefitinib resistance in non-small cell lung cancer","volume":"19","author":"He","year":"2022","journal-title":"Cancer Biol Med"},{"issue":"23","key":"10.1016\/j.bmc.2025.118372_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127610","article-title":"Design, synthesis and biological evaluation of novel c-Met\/HDAC dual inhibitors","volume":"30","author":"Dong","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118372_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112651","article-title":"Discovery of novel c-mesenchymal-epithelia transition factor and histone deacetylase dual inhibitors","volume":"204","author":"Hu","year":"2020","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.bmc.2025.118372_bb0400","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1152\/physrev.00045.2020","article-title":"Rho GTPase signaling in cancer progression and dissemination","volume":"102","author":"Crosas-Molist","year":"2022","journal-title":"Physiol Rev"},{"issue":"3","key":"10.1016\/j.bmc.2025.118372_bb0405","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.trecan.2022.12.001","article-title":"Preclinical to clinical utility of ROCK inhibitors in cancer","volume":"9","author":"Barcelo","year":"2023","journal-title":"Trends Cancer"},{"issue":"6","key":"10.1016\/j.bmc.2025.118372_bb0410","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41401-024-01236-5","article-title":"Proteomics analysis of histone deacetylase inhibitor-resistant solid tumors reveals resistant signatures and potential drug combinations","volume":"45","author":"Hao","year":"2024","journal-title":"Acta Pharmacol Sin"},{"issue":"22","key":"10.1016\/j.bmc.2025.118372_bb0415","doi-asserted-by":"crossref","first-page":"20619","DOI":"10.1021\/acs.jmedchem.4c02183","article-title":"Discovery of the first-in-class dual-target ROCK\/HDAC inhibitor with potent antitumor efficacy in vivo that trigger antitumor immunity","volume":"67","author":"Mao","year":"2024","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.bmc.2025.118372_bb0420","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/17568919.2025.2459589","article-title":"Pioneering first-in-class HDAC-ROCK inhibitors as potential multitarget anticancer agents","volume":"17","author":"Beljkas","year":"2025","journal-title":"Future Med Chem"},{"issue":"1","key":"10.1016\/j.bmc.2025.118372_bb0425","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1021\/acs.jmedchem.2c01266","article-title":"Rational design of a new RXR agonist scaffold enabling single-subtype preference for RXR\u03b1, RXR\u03b2, and RXR\u03b3","volume":"66","author":"Adouvi","year":"2023","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.bmc.2025.118372_bb0430","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071381","article-title":"Phytochemicals targeting estrogen receptors: beneficial rather than adverse effects?","volume":"18","author":"Lecomte","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"44","key":"10.1016\/j.bmc.2025.118372_bb0435","doi-asserted-by":"crossref","first-page":"27412","DOI":"10.1073\/pnas.2002997117","article-title":"Blocking PPAR\u03b3 interaction facilitates Nur77 interdiction of fatty acid uptake and suppresses breast cancer progression","volume":"117","author":"Yang","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"10.1016\/j.bmc.2025.118372_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2022.166515","article-title":"The nuclear receptor TLX (NR2E1) inhibits growth and progression of triple- negative breast cancer","volume":"1868","author":"Nelczyk","year":"2022","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"5","key":"10.1016\/j.bmc.2025.118372_bb0445","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1530\/ERC-15-0063","article-title":"Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy","volume":"22","author":"Hedrick","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.bmc.2025.118372_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176424","article-title":"Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer","volume":"969","author":"Guglielmi","year":"2024","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.bmc.2025.118372_bb0455","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1158\/2159-8290.CD-14-0697","article-title":"Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer","volume":"5","author":"van Kruchten","year":"2015","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.bmc.2025.118372_bb0460","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010758","article-title":"Expression and function of StAR in cancerous and non-cancerous human and mouse breast tissues: new insights into diagnosis and treatment of hormone-sensitive breast cancer","volume":"24","author":"Manna","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.bmc.2025.118372_bb0465","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.7150\/thno.38973","article-title":"Sensitizing triple negative breast cancer to tamoxifen chemotherapy via a redox-responsive vorinostat-containing polymeric prodrug nanocarrier","volume":"10","author":"Ma","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.bmc.2025.118372_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113870","article-title":"Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs\/HDAC inhibitors for the treatment of breast cancer","volume":"226","author":"Luo","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118372_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116185","article-title":"Novel hybrid conjugates with dual estrogen receptor \u03b1 degradation and histone deacetylase inhibitory activities for breast cancer therapy","volume":"40","author":"Zhao","year":"2021","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118372_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108561","article-title":"Retinoid X receptor agonists as selective modulators of the immune system for the treatment of cancer","volume":"252","author":"Leal","year":"2023","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.bmc.2025.118372_bb0485","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41598-021-04415-0","article-title":"The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer","volume":"12","author":"Reich","year":"2022","journal-title":"Sci Rep"},{"issue":"19","key":"10.1016\/j.bmc.2025.118372_bb0490","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13195004","article-title":"The RXR agonist MSU42011 is effective for the treatment of preclinical HER2+ breast cancer and Kras-driven lung cancer","volume":"13","author":"Leal","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.bmc.2025.118372_bb0495","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3109\/10428194.2012.656625","article-title":"Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor\/retinoid X receptor activation by histone deacetylase inhibition","volume":"53","author":"Dummer","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"10.1016\/j.bmc.2025.118372_bb0500","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1016\/j.bmcl.2013.04.067","article-title":"Discovery of a small molecular compound simultaneously targeting RXR and HADC: design, synthesis, molecular docking and bioassay","volume":"23","author":"Chen","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"issue":"6","key":"10.1016\/j.bmc.2025.118372_bb0505","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41580-020-0214-3","article-title":"The tubulin code and its role in controlling microtubule properties and functions","volume":"21","author":"Janke","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6335","key":"10.1016\/j.bmc.2025.118372_bb0510","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1126\/science.aai8764","article-title":"Microtubules acquire resistance from mechanical breakage through intralumenal acetylation","volume":"356","author":"Xu","year":"2017","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bmc.2025.118372_bb0515","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10549-020-06033-2","article-title":"HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells","volume":"186","author":"Oba","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"10.1016\/j.bmc.2025.118372_bb0520","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-08-2319","article-title":"Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression","volume":"15","author":"Suzuki","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2025.118372_bb0525","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.2147\/DDDT.S256756","article-title":"Novel HDAC\/tubulin dual inhibitor: design, synthesis and docking studies of \u03b1-phthalimido-chalcone hybrids as potential anticancer agents with apoptosis-inducing activity","volume":"14","author":"Mourad","year":"2020","journal-title":"Drug Design Devel Ther"},{"issue":"8","key":"10.1016\/j.bmc.2025.118372_bb0530","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s00018-022-04483-z","article-title":"Roles of heat-shock protein 90 and its four domains (N, LR, M and C) in calcium oxalate stone-forming processes","volume":"79","author":"Yoodee","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.bmc.2025.118372_bb0535","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1436973","article-title":"HSP90 multi-functionality in cancer","volume":"15","author":"Albakova","year":"2024","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.bmc.2025.118372_bb0540","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24055014","article-title":"Role of ganetespib, an HSP90 inhibitor, in cancer therapy: from molecular mechanisms to clinical practice","volume":"24","author":"Youssef","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"18","key":"10.1016\/j.bmc.2025.118372_bb0545","doi-asserted-by":"crossref","first-page":"7274","DOI":"10.1080\/07391102.2020.1810776","article-title":"In-silico strategies for identification of potent inhibitor for MMP-1 to prevent metastasis of breast cancer","volume":"39","author":"Shunmuga Priya","year":"2021","journal-title":"J Biomol Struct Dyn"},{"issue":"4","key":"10.1016\/j.bmc.2025.118372_bb0550","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28041771","article-title":"Identification of novel natural dual HDAC and Hsp90 inhibitors for metastatic TNBC using e-pharmacophore modeling, molecular docking, and molecular dynamics studies","volume":"28","author":"AbdElmoniem","year":"2023","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.bmc.2025.118372_bb0555","doi-asserted-by":"crossref","first-page":"505","DOI":"10.7150\/ijbs.18834","article-title":"Targeting HSP90-HDAC6 regulating network implicates precision treatment of breast cancer","volume":"13","author":"Yu","year":"2017","journal-title":"Int J Biol Sci"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808962500313X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808962500313X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:59:09Z","timestamp":1762347549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096808962500313X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":111,"alternative-id":["S096808962500313X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118372","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances of HDAC dual inhibitors in breast cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118372","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118372"}}